(Q36528708)

14 August 2017

1 reference

title

How bacteria and their products provide clues to vaccine and adjuvant development (English)

1 reference

14 August 2017

1

Gordon Dougan

1 reference

14 August 2017

Carlos Hormaeche

2

1 reference

PubMed ID

16823909

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

14 August 2017

1 reference

14 August 2017

24 Suppl 2

1 reference

14 August 2017

S2-13-9

1 reference

Toll-like receptors in the induction of the innate immune response

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Toll-like receptors and innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Innate immune recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Drosophila innate immunity: an evolutionary perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Toll-like receptors: networking for success.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

A Toll-like receptor recognizes bacterial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Immunological foundations to the quest for new vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Structural requirements of synthetic muropeptides to synergize with lipopolysaccharide in cytokine induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Human Nod1 confers responsiveness to bacterial lipopolysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

1993 Colworth Prize Lecture. The molecular basis for the virulence of bacterial pathogens: implications for oral vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Live attenuated Salmonella: a paradigm of mucosal vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Salmonella: immune responses and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Live bacteria as the basis for immunotherapies against cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Oral somatic transgene vaccination using attenuated S. typhimurium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Wild-type intracellular bacteria deliver DNA into mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Use of the stationary phase inducible promoters, spv and dps, to drive heterologous antigen expression in Salmonella vaccine strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

7 January 2021

Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

7 January 2021

Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

7 January 2021

Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

7 January 2021

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.01.104

7 January 2021

10.1016/J.VACCINE.2005.01.104

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16823909